WEBINAR
Accelerating Peptide Development: Strategies to optimize the formulation and manufacture of peptide therapeutics
Register here
Drug Development Consulting
Holistic scientific advice at each stage of drug development
Our Holistic Approach
Our Drug Development Consultants work with you to design and implement successful drug development programs. With industry leading scientific expertise across a range of technical disciplines, we help customers across all stages of development, from candidate selection to commercial launch.
Our consultants have a proven track-record of cutting across industry silos to reduce the time and cost of development. With hands-on development experience across hundreds of drug molecules and product types, we’ll help you avoid critical pitfalls, manage risks and maximise the potential for success.
Our team of drug development consultants
-
Dr Sarah Stevens
Vice President, Drug Development Sciences, Scientific Consulting
-
John McDermott
Executive Drug Development Consultant
-
Dr Vanessa Zann
Senior Drug Development Consultant
-
Dr Aruna Railkar
Senior Drug Development Consultant
Thank you for getting in touch with us.
We will send you a reply in the next 48 hours.
If you have not heard from us in the next 48 hours, do not hesitate to call us on:
UK +44 (0)115 974 9000 / US +1-800-769-3518
Ask questions to our scientific team
Leveraging decades of drug development experience
What our consultants do
-
Assess each molecule holistically to understand the complex interplay between drug substance, drug product and clinical performance
-
Listen to customers, understand goals, interpret data & guide development
-
Integrate multiple-development services and build robust development plans
Customer Benefits
-
Our consultants pre-emptively identify scientific challenges and mitigate development risks
-
Our consultants design drug development strategies that are right first time and eliminating delays
-
Our consultants streamline outsourcing, eliminate costly and time-consuming tech transfers and provides consistent scientific direction
Consultancy by stage of development
Candidate Selection - Selecting the right molecules for development
Early Development - Accelerating molecules through to proof-of-concept
Late Development - Accelerating products through to commercial manufacture
From solubility enhancement to complex oral solid dose, from paediatric dosage forms to and injectables, let our experts help you move from discovery into development, from first-in-human to proof-of-concept, and through to late phase and commercial manufacturing.
Resources
Access our resources
-
Case StudiesDCS classification of NCE - Case studyUS Biotech wanted to determine the DCS (Developability Classification System) designation for their small molecule. This included project scope and outcomes of the project.
-
Scientific PostersISSX NA 2021 - An Integrated Radiolabelled Study to Determine the Mass Balance, Metabolite Profile and Identification and absolute bioavailability of Nolasiban in Healthy Female SubjectsPresented at the 24th North American ISSX Meeting, in this poster, we determine Mass Balance, Metabolite Profile and Identification and Absolute Bioavailability of Nolasiban in Healthy Female Subjects, via an integrated radiolabelled study.
-
Info SheetIntegrated Programs: Early DevelopmentSimplify early development and accelerate to Proof-of Concept Proof-of-Concept (POC) is a key milestone in the development of a new drug candidate. At Quotient Sciences, we understand the increasing pressures on R&D budgets, therefore the need to transition molecules through early development to POC needs to be fast and cost-effective.
-
WebinarAccelerating Peptide Development: Strategies to optimize the formulation and manufacture of peptide therapeuticsThis webinar reviews the challenges when developing a peptide formulation, investigates the best route of delivery for your molecule, alongside looking into formulation strategies and manufacturing considerations, before exploring options for an integrated approach to accelerate peptide development.